The Effect of Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2B Dose Ranging Studies Genovese, M. C., Westhovens, R., Kavanaugh, A., Meuleners, L., Van der Aa, A., Harrison, P., Tasset, C. WILEY. 2016

View details for Web of Science ID 000417143405149